Chemistry:Panamesine
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | EMD-57455 |
| Pharmacokinetic data | |
| Metabolites | EMD-59983 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C23H26N2O6 |
| Molar mass | 426.469 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Panamesine (INN; developmental code name EMD-57455) is a sigma receptor antagonist that was under development by Merck as a potential antipsychotic for the treatment of schizophrenia in the 1990s but was never marketed.[1] It is a selective antagonist of both sigma receptor subtypes, the σ1 and σ2 receptors (IC50 = 6 nM).[2] In addition, the major metabolite of the drug, EMD-59983, has high affinity for the sigma receptors (IC50 = 24 nM) and the dopamine D2 (IC50 = 23 nM) and D3 receptors, with potent antidopaminergic activity.[3][4][5] Panamesine reached phase II clinical trials for schizophrenia prior to the discontinuation of its development.[1]
See also
References
- ↑ 1.0 1.1 "Panamesine". AdisInsight. http://adisinsight.springer.com/drugs/800001428.
- ↑ "Sigma receptors: biology and therapeutic potential". Psychopharmacology 174 (3): 301–19. 2004. doi:10.1007/s00213-004-1920-9. PMID 15197533.
- ↑ "Open clinical trial on the sigma ligand panamesine in patients with schizophrenia". Psychopharmacology 132 (1): 82–8. 1997. doi:10.1007/s002130050323. PMID 9272763.
- ↑ "Efficacy and safety of the sigma receptor ligand EMD 57445 (panamesine) in patients with schizophrenia: an open clinical trial". Pharmacopsychiatry 32 (2): 68–72. 1999. doi:10.1055/s-2007-979194. PMID 10333165.
- ↑ "Occupancy of striatal D(2)-like dopamine receptors after treatment with the sigma ligand EMD 57445, a putative atypical antipsychotic". Psychopharmacology 146 (1): 81–6. 1999. doi:10.1007/s002130051091. PMID 10485968.
 |  |
